drugset
drugset / Trial / NCT01359852

A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers

NCT01359852 ↗

Phase 1 Completed 20 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to evaluate \[11C\] JNJ-42491293 as a PET ligand in healthy adult volunteers.

Timeline

Start
2010-12
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-40411813 Small molecule 500 mg Oral
Subject JNJ-42491293 Diagnostic / imaging agent 300 mbq Intravenous
Subject JNJ-42491293 Diagnostic / imaging agent 370 mbq Intravenous

Indications

No indication recorded.